Genesis Global Group
Genesis Drug Discovery & Development
GD3

You will now be redirected to the GD3 website

Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.

Learn more about GD3
Search

Biochemistry & Bioanalytical

Contact our Experts

Biomarker Detection

GD3 specializes in delivering tailored protein and nucleic acid biomarker assays to accelerate drug discovery and development. With a deep focus on immunology, ophthalmology, inflammation, infectious disease, oncology, CNS, and metabolic disease, we provide both custom and off-the-shelf solutions.

Beyond standard human, mouse, rat, and non-human primate assays, our in-house capabilities enable us to develop custom biomarkers for a wide range of species. This unique strength empowers researchers to translate proteomics findings into actionable clinical insights, driving medical breakthroughs.

  • Biomarker detection methods include
    • Meso scale discovery and electrochemiluminescence (ECL)-based immunoassays
    • Colorimetric, luminescence and fluorescent-based ELISAs
    • Custom and commercially available immunoassays & ligand binding assays for analysis of protein biomarkers – either endogenous or your therapeutic agent
    • Protein-protein interactions and protein-DNA interactions
    • Reporter bioassays and cell signaling assays
    • Protein purity and aggregation analysis
    • Real-time PCR analysis
    • Differential gene expression via RNAseq
    • Western blots
    • Anti-drug antibody assays
    • Cytokine Panels
    • Biomarker Discovery
  • Biomarker examples include:
    • Metabolic Markers
    • Oncology Markers
    • Vascular Markers
    • Cytokines and Chemokines
    • Cell-Signaling Pathways
    • Alzheimer’s (Aβ38, Aβ40, Aβ42, Tau, Total Tau)
    • Kidney Injury
    • Cardiac and Muscle
    • Liver Injury
    • Inflammation
Figure 1. SMN protein was measured in whole blood using the SMN-ECL immunoassay.  Data shown from paper resulting from GD3 collaboration with client.PLoS One. 2015 Oct 15;10(10):e0139950
Figure 2. Biomarker analysis from terminal plasma samples following ONC demonstrating an increase in NfL, IL-6 and MCP-1.

Learn more about Ocular Efficacy Models